NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Price Target & More

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings data on Monday, March, 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.04. The firm earned $1.19 million during the quarter, compared to analysts' expectations of $0.75 million. Syndax Pharmaceuticals had a negative return on equity of 63.51% and a negative net margin of 2,884.34%. The business's revenue for the quarter was up 290.2% compared to the same quarter last year. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

7 brokerages have issued 1 year price objectives for Syndax Pharmaceuticals' shares. Their predictions range from $20.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $26.1667 in the next twelve months. View Analyst Ratings for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 967,476 shares, a decline of 42.3% from the March 15th total of 1,676,430 shares. Based on an average trading volume of 352,354 shares, the days-to-cover ratio is currently 2.7 days. Approximately 5.6% of the company's stock are sold short.

Some companies that are related to Syndax Pharmaceuticals include Aclaris Therapeutics (ACRS), TiGenix - American Depositary Shares (TIG), Dicerna Pharmaceuticals (DRNA), ChemoCentryx (CCXI), Akebia Therapeutics (AKBA), Achaogen (AKAO), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), AC Immune (ACIU), StemlineTherapeutics (STML), Clementia Pharmaceuticals (CMTA), Insys Therapeutics (INSY), MediciNova (MNOV), ObsEva (OBSV), Zealand Pharma (ZEAL), Concert Pharmaceuticals (CNCE), Sinovac Biotech (SVA) and Innate Pharma (IPHYF).

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

News articles about SNDX stock have been trending positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a daily sentiment score of 0.30 on Accern's scale. They also gave press coverage about the company an impact score of 44.14 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $11.23.

Syndax Pharmaceuticals has a market capitalization of $283.78 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]